CEL-SCI Corporation Releases Letter to Sh... (tion ever. We finally have the financia...)

CEL-SCI Corporation Releases Letter to Shareholders

Date:10/5/2009

tion ever. We finally have the financial resources to move forward on our programs. Our manufacturing facility is coming online, the global Phase III cancer trial for Multikine is being launched together with Teva Pharmaceuticals and Orient EuroPharma as two of our main partners, and we are racing to develop what we hope to be the first effective treatment for hospitalized H1N1 patients. We will continue to keep you up-to-date with any further material developments.

We thank you for your support as we move forward in several key areas.

Sincerely,

Geert Kersten

Chief Executive Officer

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, lack of regulatory clearance to proceed with clinical trials, an inability to duplicate the clinical results demonstrated in clinical studies that have been completed or that are initiated in the future, timely development of any potential products that can be shown to be safe and effective, unwillingness of regulatory authorities to engage in further regulatory dialogue, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2. CEL-SCI Expands H1N1 Flu Virus Work
3. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
4. CEL-SCI Posts New Corporate Presentation to Website
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Corporation Reports First Quarter Financial Results

Post Your Comments:

CEL-SCI Corporation Releases Letter to Sh...(tion ever. We finally have the financia...),Health